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Abstract
The physiological status of the individual may influence biomarkers of nutritional status. To help 
researchers with planning studies and interpreting data, we assessed the associations between 
common physiologic variables (fasting, inflammation, renal function, and pregnancy) and 29 
biomarkers of diet and nutrition measured in blood or urine in a representative sample of the adult 
US population (≥20 y; pregnancy variable and iron indicators limited to women 20–49 y) 
participating in NHANES 2003–2006. We compared simple linear regression (model 1) to 
multiple linear regression (model 2, controlling for age, sex, race-ethnicity, smoking, supplement 
use, and the physiologic factors [and urine creatinine for urine biomarkers]) and report significant 
findings from model 2. Not being fasted was positively associated with most water-soluble 
vitamins (WSV) and related metabolites (RM). Some WSV, fat-soluble vitamin (FSV) and 
micronutrient (MN) and phytoestrogen concentrations were lower in the presence of inflammation 
(C-reactive protein ≥5 mg/L), while fatty acids and most iron indicators were higher. Most 
WSV&RM were higher when renal function was impaired (estimated glomerular filtration rate 
<60 mL/(min·1.73 m2). Most WSV, FSV&MN, and fatty acid concentrations were higher in 
pregnant compared to non-pregnant women, but vitamins A and B-12 and most iron indicators 
were lower. The estimated changes in biomarker concentrations with different physiologic status 
were mostly small to moderate (≤|25%|) and generally similar between models; renal function, 
however, showed several large differences for WSV&RM. This descriptive analysis of associations 
between physiologic variables and a large number of nutritional biomarkers showed that 
controlling for demographic variables, smoking, and supplement use generally did not change the 
interpretation of bivariate results. The analysis serves as a useful basis for more complex future 
research.
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INTRODUCTION
Biomarkers are used to assess nutritional status and associated health outcomes. Physiologic 
variables such as the fasting and health status of the individual can influence biomarkers and 
may confound study results (1, 2). While appropriate study design and data analysis may 
minimize the extent of confounding, practical considerations sometimes interfere with the 
research plan and investigators may ask whether they can meaningfully interpret data 
obtained from participants under less than ideal conditions.
Some biomarkers are short-term status indicators (e.g., serum folate [S-FOL]4 and 4-
pyridoxic acid [4PA], the end product of vitamin B-6 catabolism) and may therefore be 
influenced by recent dietary intake and elevated in specimens from non-fasting participants 
(3). Several biomarkers are notably influenced by inflammation, being either positive (e.g., 
serum ferritin [FER]) or negative (e.g., retinol binding protein) acute phase proteins, or 
because the inflammatory response reduces circulating nutrient concentrations (e.g., iron) 
(4–7). The association between the systemic inflammatory response and biomarkers has 
been studied in detail for vitamins A (8, 9), B-6 (10–13), and iron status (14). The 
associations between impaired renal function and increased serum total homocysteine (tHcy; 
15–18) and methylmalonic acid (MMA; 19–21) concentrations or altered iron status (22, 23) 
have also been documented. With chronic kidney disease (CKD) increasing in the United 
States (24) as rates of obesity (25) and diabetes (26) have been climbing over the last few 
decades, it is important to understand the effect of impaired renal function on nutritional 
biomarkers. Pregnancy generally increases micronutrient requirements because of the 
increased needs of the fetus, which in turn often depresses blood concentrations (3, 27).
In addition to collecting biological specimens for biomarker measurements to assess the 
nutritional status of the US population, the NHANES collects a wealth of information on the 
health status of the participants and records the fasting status. To provide a comprehensive 
picture of whether different classes of biomarkers of diet and nutrition are associated with 
common physiologic variables (fasting, inflammation, renal function, and pregnancy), we 
conducted a descriptive bivariate analysis using cross-sectional data from the adult US 
population participating in NHANES 2003–2006. We also compared simple and multiple 
linear regression after controlling for a standard set of covariates that emerged as important 
factors in class-specific analyses conducted as part of this supplement (see accompanying 
papers). The findings from this study will help researchers with planning studies involving 
nutritional biomarkers and interpreting data.
SUBJECTS AND METHODS
The NHANES collects cross-sectional data on the health and nutritional status of the civilian 
non-institutionalized US population (28). The 2003–2006 survey cycles provide a stratified, 
4Abbreviations used: 25OHD, 25-hydroxyvitamin D; 4PA, 4-pyridoxic acid; B-12, total cobalamin; BI, body iron; CAR, carotenes; 
DAZ, daidzein; DMA, O-desmethylangolensin; EQU, equol; ETD, enterodiol; ETL, enterolactone; FER, ferritin; GEN, genistein; 
HbAA, acrylamide hemoglobin adduct; HbGA, glycidamide hemoglobin adduct; MMA, methylmalonic acid; MN, micronutrient; 
NCHS, National Center for Health Statistics; PLP, pyridoxal-5′-phosphate; RBC-FOL, RBC folate; RM, B-vitamin related 
metabolites; S-FOL, serum folate; sTfR, soluble transferrin receptor; tFA, total fatty acids; tHcy, total homocysteine; uI, urine iodine; 
VIA, retinol; VIC, ascorbic acid; VIE, alpha-tocopherol; XAN, xanthophylls.
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multistage, probability sample designed to represent the American population on the basis of 
age, sex, and race-ethnicity. All respondents gave their informed consent, and the NHANES 
protocol was reviewed and approved by the NCHS Research Ethics Review Board.
Laboratory methods
Twenty-nine biomarkers of diet and nutritional status were analyzed by the CDC laboratory 
during all or part of NHANES 2003–2006 as part of 6 classes: water-soluble vitamins 
(WSV) and related metabolites (RM), fat-soluble vitamins (FSV) and micronutrients (MN), 
fatty acids, trace elements, phytoestrogens, and acrylamide hemoglobin adducts (Table 1). 
For additional information on how certain dependent variables were calculated, see 
Supplemental Methods 1. Laboratory method details are provided elsewhere (29, 30).
Study variables
Four independent variables were assessed: fasting, presence of inflammation, renal function, 
and pregnancy (Table 1). The definition of renal function is described in Supplemental 
Methods 1.
Analytic sample
All Mobile Examination Center-examined participants aged ≥20 y in the NHANES 2003–
2004 and 2005–2006 with at least 1 biomarker of interest were eligible for inclusion in the 
study. We limited iron indicators (FER, soluble transferrin receptor [sTfR] and body iron 
[BI]) and the pregnancy variable to women 20–49 y (no data for iron indicators for other 
adults; no pregnant women older than 49 y). Depending on whether the biomarker was 
analyzed in both survey periods and on the full sample or a subsample, data were available 
for between ~1400 and nearly 9000 adult NHANES participants (Supplemental Table 1). We 
did not exclude participants based on any health conditions because our intent was to assess 
associations in the general population.
Statistical analyses
We assessed bivariate associations for categorical variables by calculating the geometric 
means (arithmetic means for ascorbic acid [VIC], 25-hydroxyvitamin D [25OHD], and BI) 
and 95% CI for each category and Spearman correlations for continuous variables (fasting, 
inflammation, and renal function). We used the Wald F test to compare means across 
categories and conducted pairwise comparisons if the overall Wald F test was significant and 
there were more than 2 categories. Linear regression was used to assess the association of 
the physiologic variables without (simple = model 1) and with (multiple = model 2) 
controlling for additional covariates that emerged as important factors in class-specific 
analyses conducted as part of this supplement: age, sex, race-ethnicity, smoking, and 
supplement use (and urine creatinine for urine biomarkers), in addition to the other 
physiologic variables. For a graphical representation of changes in beta coefficients from 
model 1 to model 2, see Supplemental Fig. 1. We assessed the magnitude of association by 
presenting the percent change in biomarker concentration with change in each covariate 
holding all remaining covariates constant (31). For biomarkers with accepted cutoff values 
for abnormal concentrations, we also calculated prevalence estimates by variable categories 
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(Supplemental Methods 2). Statistical analyses were carried out using SAS for Windows 
software version 9.2 (SAS Institute, Cary, NC) and SAS-callable SUDAAN (SUDAAN 
Release 10.0, 2008 RTI, Research Triangle Park, NC). Analyses using SUDAAN software 
accounted for the complex survey design by incorporating the survey weights to account for 
the unequal probabilities of selection and adjustment for non-response and by using a Taylor 
series linearization to calculate variance estimates. We flagged 2-sided P-values as 
statistically significant if <0.05.
RESULTS
Descriptive information for the civilian non-institutionalized US population in various 
subsamples of the NHANES 2003–2006 showed that approximately half of the sample was 
evaluated after ≥8 h of fasting, slightly more than 20% had elevated C-reactive protein 
(CRP) concentrations indicative of inflammation, slightly less than 20% had some form of 
CKD, and ~6% of women 20–49 y were pregnant (Supplemental Table 2). We observed 
correlations between the continuous independent variables and the biomarkers that were 
mostly weak (|rs|<0.2) and inconsistent with regards to direction and significance 
(Supplemental Table 3). However, we observed moderate (0.2≤|rs|<0.44) and significant 
correlations in the following cases: between inflammation and pyridoxal-5′-phosphate 
(PLP), carotenes (CAR), and xanthophylls (XAN) (all negative); between inflammation and 
SFA (positive); and between renal function and B vitamins and RM (RBC-FOL, 4PA, tHcy 
and MMA), retinol (VIA), and alpha-tocopherol (VIE) (all negative).
Fasting
Fasting status was significantly associated with WSV & RM (except total cobalamin 
[B-12]), VIE, CAR, and with all phytoestrogens; however, it was not significantly associated 
with concentrations of most FSV & MN, iron and iodine status indicators, and acrylamide 
hemoglobin adducts (Table 2). Estimated changes in biomarker concentrations between non-
fasting and fasting persons (<3 h vs. ≥8 h) were mostly similar before (model 1) and after 
controlling for covariates (model 2) (Table 5 and Supplemental Fig. 1, panel A). As derived 
from model 2, mean concentrations of most WSV and VIE were slightly but significantly 
higher (≤10%; 3.4 μmol/L for VIC) in non-fasting persons, but for MMA (21%) and 4PA 
(28%) we observed larger percent differences.
Inflammation
Inflammation was significantly associated with 19 out of 29 biomarkers (Table 3). Most 
FSV & MN (except VIE), fatty acids, and the iron and iodine status indicators were 
significantly associated with the inflammatory biomarker, CRP. Some WSV (S-FOL, RBC-
FOL, PLP, and VIC), two phytoestrogens (O-desmethylangolensin [DMA] and enterolactone 
[ETL]), and hemoglobin glycidamide adduct (HbGA) were also significantly associated. 
Estimated changes in biomarker concentrations between persons with and without 
inflammation were mostly similar between models 1 and 2 (Table 5 and Supplemental Fig. 
1, panel C). As derived from model 2, some analyte concentrations were significantly lower 
in the presence of inflammation (S-FOL, PLP, VIC, VIA, CAR, XAN, 25OHD, DMA, 
enterodiol [ETD], ETL, hemoglobin acrylamide adduct [HbAA]), while others were 
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significantly higher (RBC-FOL, SFA, MUFA, PUFA, total fatty acids [tFA], FER, BI, 
HbGA). Differences were small (≤10% for S-FOL, RBC-FOL, VIA, SFA, PUFA, tFA, 
HbAA, HbGA; 3.9 μmol/L for 25OHD), moderate (>10–25% for CAR, XAN, MUFA, FER, 
ETD; 8.2 μmol/L for VIC; 0.7 mg/kg for BI), or large (>25% for PLP, DMA, ETL).
Renal function
Impaired renal function was significantly associated with 20 out of 29 biomarkers (Table 3). 
Biomarkers not associated with renal function were XAN, PUFA, FER, BI, and all 
phytoestrogens except for ETL. Estimated changes in biomarker concentrations between 
persons with and without impaired renal function were less similar between models 1 and 2 
than observed for fasting and inflammation (Table 5 and Supplemental Fig. 1, panel E). 
While we noted attenuation after controlling for covariates, mean concentrations of most 
WSV & RM (except PLP and VIC) were significantly higher in stage 3–5 CKD compared to 
normal renal function, with the largest percent differences observed for 4PA (66%), MMA 
(42%), and tHcy (32%). Whereas several FSV & MN (VIA, VIE, CAR) and fatty acids 
(SFA, MUFA, tFA) showed significant percent differences in model 1, only VIA (20%) and 
SFA (-5%) retained a small to moderate significant percent difference between persons with 
and without impaired renal function after controlling for covariates (model 2). We noted 
strong attenuation after controlling for covariates for urine iodine (uI) and the 2 acrylamide 
hemoglobin adducts; only HbGA retained a small (8%) significant percent difference 
between persons with and without impaired renal function.
Pregnancy
Pregnancy was significantly associated with 17 out of 29 biomarkers, most WSV & RM 
(except PLP and 4PA), most FSV & MN (except CAR), fatty acids, most iron indicators 
(except sTfR), and HbAA (Table 4). Estimated changes in biomarker concentrations 
between pregnant and non-pregnant women were generally similar between the 2 models 
(Table 5 and Supplemental Fig. 1, panel F). While we noted modest attenuation after 
controlling for covariates, folate (both serum [18%] and RBC [26%]), 4PA (34%) and VIC 
(3.8 μmol/L) concentrations were significantly higher, while B-12 (22%) and tHcy (30%) 
concentrations were significantly lower in pregnant women. FSV & MN and fatty acid 
concentrations were significantly higher (12–32%; 6.6 μmol/L for 25OHD) in pregnant 
women, except for VIA concentrations which were 22% lower. Iron status was lower in 
pregnant women, with significantly lower FER (33%) and BI (1.4 mg/kg) levels. Pregnant 
women had slightly but significantly lower HbAA levels but similar HbGA levels compared 
to non-pregnant women. We found no significant differences in phytoestrogen 
concentrations between pregnant and non-pregnant women.
DISCUSSION
In this descriptive analysis of cross-sectional data for 29 biomarkers of diet and nutrition 
from a nationally representative sample of American adults participating in NHANES 2003–
2006 we observed the following: fasting and renal function were associated with most WSV 
& RM; inflammation was associated with most FSV & MN, fatty acids, most iron status 
indicators, and acrylamide hemoglobin adducts; and pregnancy was associated with most 
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WSV & RM, FSV & MN, fatty acids, and most iron status indicators. The estimated 
changes in biomarker concentrations with different physiologic status were generally small 
to moderate (≤|25%|) and for the most part similar before and after controlling for a standard 
set of covariates.
Fasting
Most WSV & RM were found at lower concentrations in fasting persons before and after 
controlling for covariates, most likely due to the rapid clearance of these nutrients from the 
plasma compartment in just a few hours after a meal (3). Of the FSV & MN, only VIE 
showed slightly higher (4%) concentrations in the fed state after controlling for covariates. 
VIE is closely correlated to its carrier protein, LDL-cholesterol, which also increases 
following meals. As expected, we did not find an association of fasting with VIA (dietary 
vitamin A is rapidly taken-up by the liver which closely regulates circulating VIA 
availability [27]), vitamin D (requirement is mostly met by exposure to sunlight [32]), iron 
status indicators (are weakly correlated to recent dietary intake of total iron [33]), and 
hemoglobin adducts of acrylamide (reflect time-weighted exposure to acrylamide over the 
past 4 mo [34]). Although we did not observe significant differences in phytoestrogen 
concentrations between fasting (≥8 h) and non-fasting (<3 h) persons, concentrations were 
consistently higher in fasting persons compared to those who had a shorter fast (3–<8 h). 
This may reflect the time needed for absorption, distribution and clearance, which has been 
reported as 5–10 h for GEN and DAZ (35), but longer for compounds (e.g., EQU) that are 
metabolized in the colon and recirculated before urine excretion (36). Finally, the 
significantly higher uI concentration in non-fasting compared to fasting persons after 
controlling for covariates, is most likely a result of the creatinine adjustment.
Inflammation
Of the 19 biomarkers of diet and nutrition that were associated with inflammation, 9 had 
lower and 10 had higher concentrations in persons with an inflammatory response. For 
example, PLP, CAR, and XAN concentrations were 29%, 18%, and 21% lower, respectively, 
when CRP was elevated after we controlled for covariates, which is consistent with data 
shown by others (5, 10–13, 37–39). Although the mechanism is not understood, we also 
found an inverse relationship between CRP and the isoflavone DMA (a metabolite of DAZ; 
36% lower) and the lignans ETD and ETL (21% and 38% lower, respectively). Consistent 
with these observations, Chun et al. (40) showed that the dietary intake of some isoflavones 
(DAZ and GNS) was inversely associated with CRP and Pellegrini et al. (41) showed that 
lignan intake was inversely associated with other vascular inflammation biomarkers.
Perhaps the most well-known consequence of inflammation on a nutritional biomarker is its 
effect on the positive acute-phase iron storage protein ferritin. After controlling for 
covariates, we found 25% higher FER concentrations, no difference in sTfR concentrations, 
and 0.7 mg/kg higher BI levels in persons with compared to without inflammation. This 
confirms that in a generally healthy population, sTfR does not appear to be affected by 
inflammation (42). A novel observation in the present study was that fatty acid 
concentrations were slightly higher (3–11%) in those with elevated CRP. As triglyceride 
fatty acids consist of 80% SFA and MUFA (43), and triglycerides were shown to be 
Haynes et al. Page 6
J Nutr. Author manuscript; available in PMC 2016 March 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
independently and positively associated with CRP in the NHANES III (44), our observation 
appears to support the connection between inflammation and triglycerides. Duncan et al. (5) 
aimed to examine the effect of inflammation on micronutrient concentrations with the intent 
of developing local hospital guidelines to aid in the interpretation of nutrition results. Similar 
to our study, they found lower PLP, VIC, VIA and 25OHD concentrations in patients who 
had elevated CRP concentrations leading the authors to suggest that interpretation of 
micronutrient concentrations requires knowledge of a patient’s inflammatory status.
Renal function
Impaired renal function was associated with 20 out of 29 biomarkers included in our study, 
and the differences in biomarker concentrations between persons with stage 3–5 CKD 
compared to those with normal renal function were large (>25%) for several biomarkers 
(4PA, MMA, tHcy) after controlling for covariates. The strong association between renal 
insufficiency and elevated tHcy (16–19) or MMA (18–20) concentrations, independent of 
the B vitamin status, has been shown before and is likely because the reduced glomerular 
filtration rate can no longer efficiently clear these metabolites (45). The same probably 
applies to elevated 4PA concentrations, also found in older participants with impaired renal 
function in the British National Diet and Nutrition survey (13).
Pregnancy
Blood levels of WSV, VIA, and iron indicators are known to decrease during pregnancy (3, 
27, 46, 47). Accordingly, after controlling for covariates, we found much reduced B-12 
(22%), VIA (22%), FER (33%), and BI (1.4 mg/kg) levels in pregnant women. Despite the 
lower B-12 concentrations, MMA concentrations were not significantly different. Other 
studies reported decreasing B-12 concentrations throughout pregnancy, but only slightly 
fluctuating MMA concentrations within the normal range (48, 49). Contrary to textbook 
knowledge, we found higher S-FOL (18%), RBC-FOL (26%) and VIC (3.8 μmol/L) 
concentrations in pregnant women, even after controlling for supplement use to account for 
the higher proportion of pregnant women consuming dietary supplements (80% compared to 
only 55% of non-pregnant women). Other cross-sectional data from outpatient populations 
also showed an increase in folate reference ranges during pregnancy (50) and no difference 
in mean plasma VIC between pregnant and non-pregnant women (51). The much lower tHcy 
(30%) and slightly higher 25OHD (7%) concentrations in our study are consistent with 
previous observations (52–56). Also consistent with common knowledge that blood 
concentrations of VIE increase during pregnancy, parallel with an increase in total lipids 
(46), we observed higher VIE (22%), CAR (12%), XAN (32%), and higher fatty acid 
concentrations (19–29%) in pregnant women. The slightly lower (10%) HbAA levels in 
pregnant women may be a result of hemodilution.
Strengths and weaknesses
The present study is to our knowledge the first that has assessed the association of 4 
common physiologic variables, typically considered when planning or evaluating data from 
nutrition studies, with a large number of biomarkers of diet and nutrition crossing several 
classes of nutrients. The large sample size of the NHANES in combination with the 
availability of objective biochemical data to study the effects of inflammation, renal function 
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and pregnancy made it possible to assess differences in biomarker concentrations even for 
rare conditions (~8% of the NHANES participants had stage 3–5 CKD and ~6% of women 
were pregnant). Furthermore, additional analyses for the same 29 biomarkers are presented 
as part of this journal supplement to assess their association with sociodemographic and 
lifestyle variables. While we controlled for a standard set of covariates that emerged as 
important factors in class-specific analyses conducted as part of this supplement, the 
interpretation of our findings may be limited by other confounding variables. Developing 
specific multi-variate models for each biomarker was beyond the scope of the current 
analysis. The benefit of this analysis lies in the wide spectrum covered and the consistent 
approach taken so that observations can be compared across biomarkers.
Conclusions
The selected physiologic variables studied in this analysis were generally weakly to 
moderately associated with 29 biomarkers of diet and nutrition. Controlling for demographic 
variables, smoking and supplement use did not change the interpretation of the bivariate 
analysis in most cases. These descriptive analyses will help researchers better plan for future 
studies and interpret resulting data.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
List of dependent and independent variables including stratification
Nutrient classes and biomarkers of diet and nutrition
(dependent variables)
Water-soluble vitamins (WSV) and related metabolites (RM):
• Serum folate (S-FOL)
• RBC folate (RBC-FOL)
• Serum pyridoxal-5′-phosphate (PLP)
• Serum 4-pyridoxic acid (4PA)
• Serum total cobalamin (B-12)
• Plasma total homocysteine (tHcy)
• Plasma methylmalonic acid (MMA)
• Serum ascorbic acid (VIC)
Fat-soluble vitamins (FSV) and micronutrients (MN):
• Serum retinol (VIA)
• Serum alpha-tocopherol (VIE)
• Serum carotenes (CAR, sum of 3 analytes)
• Serum xanthophylls (XAN, sum of 3 analytes)
• Serum 25-hydroxyvitamin D (25OHD)
Fatty acids:
• Plasma saturated (SFA, sum of 6 analytes)
• Plasma monounsaturated (MUFA, sum of 7 analytes)
• Plasma polyunsaturated (PUFA, sum of 11 analytes)
• Plasma total fatty acids (tFA, sum of 24 analytes)
Trace elements:
• Serum ferritin (FER)
• Serum soluble transferrin receptor (sTfR)
• Serum body iron (BI, calculated from the ratio of sTfR to FER)
• Urine iodine (uI)
Phytoestrogens:
• Urine genistein (GEN)
• Urine daidzein (DAZ)
• Urine equol (EQU)
• Urine O-desmethylangolensin (DMA)
• Urine enterodiol (ETD)
• Urine enterolactone (ETL)
Acrylamide hemoglobin adducts:
• Hemolyzed blood acrylamide hemoglobin adduct (HbAA)
• Hemolyzed blood glycidamide hemoglobin adduct (HbGA)
Physiologic variables
(independent variables)
Fasting status:
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Nutrient classes and biomarkers of diet and nutrition
(dependent variables)
• <3 h
• 3–<8 h
• ≥8 h
Inflammation (based on C-reactive protein [CRP]):
• No, CRP <5 mg/L
• Yes, CRP ≥5 mg/L (57)
Renal function (defined by estimated glomerular filtration rate [eGFR] using the National Kidney Foundation classification system to 
determine stages of chronic kidney disease (CKD [58]):
• Normal, eGFR ≥60 mL/(min·1.73 m2) and absence of albuminuria
• Stage 1 or 2 of CKD, eGFR ≥60 mL/(min·1.73 m2) and presence of albuminuria
• Stage 3–5 CKD, eGFR <60 mL/(min·1.73 m2)
Pregnancy (ascertained at the time of the health examination by the value from urine pregnancy test and from self-reported pregnancy status; 
for women who were interviewed but not examined, pregnancy status could not be determined):
• No
• Yes
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Table 4
Unadjusted mean biomarker concentrations by pregnancy categories for women 20–49 y of age, NHANES 
2003–20061,2,3,4,5
Analyte
(matrix)6, unit Overall
Pregnant
P-value7No Yes
Water-soluble vitamins and related metabolites
 FOL (S), μg/L 11.2 (10.8 – 11.5) 11.0 (10.6 – 11.3) 14.4 (13.4 – 15.5) <0.0001
 FOL (RBC), μg/L 259 (251 – 266) 254 (247 – 261) 347 (330 – 366) <0.0001
 PLP (S), nmol/L 43.0 (39.5 – 46.8) 43.0 (39.5 – 46.8) 42.7 (35.6 – 51.2) 0.93
 4PA (S), nmol/L 26.9 (24.6 – 29.4) 26.2 (24.1 – 28.4) 38.6 (28.6 – 51.9) 0.0047
 B-12 (S), ng/L 443 (429 – 458) 449 (433 – 464) 372 (348 – 398) <0.0001
 tHcy (P), μmol/L 6.67 (6.53 – 6.82) 6.86 (6.71 – 7.02) 4.35 (4.18 – 4.51) <0.0001
 MMA (P), nmol/L 120 (113 – 127) 121 (114 – 128) 106 (92.1 – 123) 0.05
 VIC (S), μmol/L 53.7 (51.3 – 56.1) 53.1 (50.7 – 55.6) 63.3 (60.5 – 66.0) <0.0001
Fat-soluble vitamins and (micro)nutrients
 VIA (S), μg/dL 51.3 (49.9 – 52.7) 52.3 (50.8 – 53.9) 40.3 (37.9 – 42.8) <0.0001
 VIE (S), mg/dL 1.07 (1.04 – 1.10) 1.05 (1.02 – 1.08) 1.23 (1.17 – 1.30) <0.0001
 CAR (S), μg/dL 61.1 (59.0 – 63.3) 60.7 (58.4 – 63.1) 66.7 (61.4 – 72.5) 0.06
 XAN (S), μg/dL 22.1 (20.9 – 23.4) 21.7 (20.4 – 23.0) 29.0 (26.7 – 31.6) <0.0001
 25OHD (S), nmol/L 59.8 (57.4 – 62.2) 59.2 (56.8 – 61.6) 68.9 (63.7 – 74.2) 0.0003
 SFA (P), mmol/L 3.53 (3.40 – 3.66) 3.49 (3.35 – 3.63) 4.28 (4.02 – 4.56) <0.0001
 MUFA (P), mmol/L 2.36 (2.28 – 2.44) 2.33 (2.26 – 2.42) 2.87 (2.67 – 3.08) <0.0001
 PUFA (P), mmol/L 4.76 (4.64 – 4.88) 4.73 (4.61 – 4.85) 5.42 (5.11 – 5.75) <0.0001
 tFA (P), mmol/L 10.7 (10.4 – 10.9) 10.6 (10.3 – 10.9) 12.6 (11.8 – 13.5) <0.0001
Trace elements
 FER (S), μg/L 39.9 (38.2 – 41.7) 40.9 (39.1 – 42.8) 27.1 (23.4 – 31.4) <0.0001
 sTfR (S), mg/L 3.46 (3.39 – 3.53) 3.46 (3.39 – 3.54) 3.40 (3.24 – 3.55) 0.46
 BI (S), mg/kg 5.65 (5.46 – 5.83) 5.73 (5.54 – 5.92) 4.30 (3.66 – 4.94) 0.0001
 uI (U), μg/L 116 (107 – 125) 115 (107 – 123) 137 (100 – 189) 0.22
Phytoestrogens
 GEN (U), μg/L 23.0 (19.1 – 27.7) 23.1 (19.0 – 28.1) 21.5 (16.2 – 28.6) 0.64
 DAZ (U), μg/L 50.7 (42.5 – 60.4) 51.1 (42.5 – 61.4) 45.6 (34.2 – 60.8) 0.47
 EQU (U), μg/L 7.38 (6.35 – 8.57) 7.34 (6.30 – 8.55) 7.91 (5.60 – 11.2) 0.66
 DMA (U), μg/L 3.97 (3.26 – 4.82) 4.05 (3.29 – 5.00) 2.99 (1.84 – 4.87) 0.26
 ETD (U), μg/L 36.7 (31.6 – 42.6) 35.9 (30.5 – 42.1) 48.9 (30.8 – 77.8) 0.22
 ETL (U), μg/L 266 (224 – 315) 265 (221 – 318) 275 (190 – 399) 0.85
Acrylamide hemoglobin adducts
 HbAA (B), pmol/g Hb 63.9 (59.7 – 68.4) 64.9 (60.3 – 69.9) 46.4 (41.4 – 52.0) <0.0001
 HbGA (B), pmol/g Hb 64.6 (60.7 – 68.9) 64.9 (60.7 – 69.5) 59.2 (51.4 – 68.1) 0.25
1
Biomarker concentrations represent geometric means (arithmetic means for vitamin C, vitamin D, and body iron) and 95% CI.
225OHD, 25-hydroxyvitamin D; 4PA, 4-pyridoxic acid; B-12, total cobalamin; BI, body iron; CAR, carotenes; DAZ, daidzein; DMA, O-
desmethylangolensin; EQU, equol; ETD, enterodiol; ETL, enterolactone; FER, ferritin; FOL, folate; HbAA, acrylamide hemoglobin adduct; 
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HbGA, glycidamide hemoglobin adduct; GEN, genistein; MMA, methylmalonic acid; PLP, pyridoxal-5′-phosphate; sTfR, soluble transferrin 
receptor; tFA, total fatty acids; tHcy, total homocysteine; uI, urine iodine; VIA, retinol; VIC, ascorbic acid; VIE, alpha-tocopherol; XAN, 
xanthophylls.
3SI conversion factors are as follows: B-12, ×0.738 (pmol/L); DAZ, ×3.93 (nmol/L); DMA, ×3.87 (nmol/L); EQU, ×4.13 (nmol/L); ETD, ×3.31 
(nmol/L); ETL, ×3.35 (nmol/L); FER, ×2.247 (pmol/L); FOL, ×2.266 (nmol/L); GEN, ×3.70 (nmol/L); uI, ×7.88 (nmol/L); VIA, ×0.03491 
(μmol/L); VIE, ×23.218 (μmol/L).
4
MMA, SFA, MUFA, PUFA, tFA, HbAA and HbGA data only available for NHANES 2003–2004; PLP, 4PA, VIA, VIE, CAR, and XAN data only 
available for NHANES 2005–2006.
5Sample sizes for each biomarker by covariate categories can be found in Supplemental Table 1.
6S, serum; P, plasma; U, urine; B, whole blood.
7P-value based on Wald F test, which tests whether at least 1 of the means across the categories is significantly different.
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 m
L/
(m
in·
1.7
3 m
2 )
 an
d p
res
en
ce
 of
 al
bu
m
in
ur
ia
; s
ta
ge
 3
–5
 C
K
D
 w
as
 d
ef
in
ed
 a
s e
G
FR
 <
60
 m
L/
(m
in·
1.7
3 m
2 )
.
7 S
im
pl
e 
lin
ea
r r
eg
re
ss
io
n 
(m
od
el 
1).
8 M
ul
tip
le
 li
ne
ar
 re
gr
es
sio
n 
m
od
el
 c
on
tro
lle
d 
fo
r a
ge
, s
ex
, 
ra
ce
-e
th
ni
ci
ty
,
 
sm
o
ki
ng
, s
up
pl
em
en
t u
se
, f
as
tin
g,
 in
fla
m
m
at
io
n,
 a
nd
 re
na
l f
un
ct
io
n 
(an
d u
rin
e c
rea
tin
ine
 fo
r u
rin
e b
iom
ark
er
s) 
(m
od
el 
2).
9 M
ul
tip
le
 li
ne
ar
 re
gr
es
sio
n 
m
od
el
 fo
r w
o
m
en
 2
0–
49
 y
 co
nt
ro
lle
d 
fo
r p
re
gn
an
cy
 in
 a
dd
iti
on
 to
 th
e 
ab
ov
e 
m
en
tio
ne
d 
va
ria
bl
es
 (m
od
el 
2).
10
N
/A
 a
s a
ll 
su
bje
cts
 w
ere
 fa
st
in
g 
fo
r ≥
8 
h.
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*
Ch
an
ge
 is
 si
gn
ifi
ca
nt
ly
 d
iff
er
en
t f
ro
m
 0
; P
 
<
0.
05
.
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